Immunosuppression procedure codes
Metadata
- Coding system
- SNOMED CT (UK Clinical Edition)
- Coding system release
- 40.2.0
- Organisation
- NHSD Primary Care Domain Refsets
- Codelist ID
- nhsd-primary-care-domain-refsets/imtrtatrisk1_cod
- Version Tag
- 20250627
- Version ID
- 0fb7cd20
- Number of codes included
- 141
About
Description
Taken from the `IMTRTATRISK1_COD` refset published by NHSD. Contains public sector information licensed under the UK Open Government Licence v3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
This codelist was imported automatically. The following codes were not found in the SNOMED CT (UK Clinical Edition) dictionary and so excluded from this codelist: 42598211000001107, 42577111000001105, 42652011000001100, 42220011000001101, 42638411000001107.
This may be because this codelist contains both clinical terms and medications. In which case you may need to create another codelist for the missing clinical/medication codes.
References
Codelists are developed by a broad community of users for individual study purposes, which may or may not meet the needs of other studies. They should not be thought of as universal definitions of a particular condition.
We don't offer any guarantees about what they do or don't identify. Users should carefully check that any codelist meets their needs, and seek clinical input where appropriate.
code | term |
---|---|
106531000119101 | Long-term current use of penicillamine |
1141994004 | Rituximab, cyclophosphamide, etoposide, vincristine, prednisone antineoplastic chemotherapy regimen |
1148692008 | Radiation therapy following chemotherapy |
1149431000000106 | Intraoperative electron radiotherapy |
1156505006 | External beam radiation therapy using carbon ions |
1156506007 | External beam radiation therapy using photons |
1156524009 | Intensity modulated external beam neutron radiation therapy |
1156525005 | Mixed beam external beam radiation therapy |
1156528007 | External beam radiation therapy using particle spot scanning technique |
1156529004 | External beam radiation therapy using particle passive scattering technique |
1156667005 | Penicillamine therapy |
1156961008 | Chimeric antigen receptor T-cell immunotherapy |
1167481000000105 | Intra-arterial injection of antineoplastic agent into bilateral ophthalmic arteries using fluoroscopic guidance with contrast |
1172516002 | High-dose chemotherapy with stem cell transplant |
1179723002 | Administration of tocilizumab |
1179729003 | Administration of sarilumab |
12149006 | Chemotherapy administration, subcutaneous, with local anesthesia |
1217525002 | Injection of antineoplastic agent into neoplasm of brain tissue |
12240661000119103 | Long term systemic steroid user |
1254741007 | Intensification antineoplastic therapy regimen |
1254742000 | Delayed intensification antineoplastic therapy regimen |
1255831008 | Chemotherapy for malignant neoplastic disease using targeted agent |
1255834000 | Administration of antineoplastic chemotherapy into peritoneal cavity |
1255853005 | Injection of immunotherapeutic agent |
1255904006 | Administration of palliative antineoplastic agent |
1259200004 | Neoadjuvant antineoplastic chemotherapy |
1264382006 | Follow-up for combined therapy of radiation therapy and chemotherapy |
1264383001 | Follow-up for combined therapy of surgery and chemotherapy |
1264385008 | Follow-up for combined therapy of surgery, radiation therapy, and chemotherapy |
1269418000 | Upadacitinib therapy |
1269441008 | Ixekizumab therapy |
1269442001 | Baricitinib therapy |
1269443006 | Belantamab mafodotin therapy |
1269444000 | Belatacept therapy |
1269445004 | Guselkumab therapy |
1287649000 | Cellular immunotherapy |
1287683007 | Risankizumab therapy |
1287737006 | Sarilumab therapy |
1287761004 | Arsenic therapy |
1287762006 | Arsenic compound therapy |
1290226008 | Administration of antineoplastic agent via intravenous route |
1290228009 | Administration of antineoplastic agent via subcutaneous route |
15625411000119109 | Long-term current use of apremilast |
15625451000119105 | Long-term current use of tofacitinib |
16890821000119107 | Long-term current use of ixekizumab |
169335009 | External beam radiotherapy with surgery and chemotherapy |
169336005 | External beam radiation therapy with chemotherapy |
169343004 | Bone marrow suppression using irradiation |
169396008 | Radiomimetic chemotherapy |
169397004 | Radiochemotherapy by local infiltration |
169398009 | Radiochemotherapy: to stop spread |
169399001 | Radiochemotherapy via oral route |
169400008 | Radiochemotherapy via intravenous route |
169402000 | Intraarterial radiochemotherapy |
169403005 | Intracavitary radiochemotherapy |
171765004 | Intrathecal injection of chemotherapeutic agent |
174236121000119109 | Long-term current use of baricitinib |
183023001 | Transplant immunosuppression |
183651009 | Chemotherapy follow-up |
22733003 | Chemotherapy for non-malignant neoplasm |
230857009 | Injection of chemotherapeutic substance into subcutaneous reservoir |
232681000000103 | Chemotherapy delivery |
235331000000103 | Delivery of oral chemotherapy for neoplasm |
235391000000102 | Delivery of chemotherapy for neoplasm |
238831000000103 | Delivery of exclusively oral chemotherapy for neoplasm |
238841000000107 | Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at first attendance |
238851000000105 | Delivery of complex parenteral chemotherapy for neoplasm at first attendance |
238861000000108 | Delivery of simple parenteral chemotherapy for neoplasm at first attendance |
239071000000100 | Delivery of subsequent element of cycle of chemotherapy for neoplasm |
265760000 | Intravenous chemotherapy |
265761001 | Intramuscular chemotherapy |
265762008 | Subcutaneous chemotherapy |
266719004 | Oral chemotherapy |
268500004 | Administration of prophylactic chemotherapy |
275830000 | Reverse barrier nursing |
29391003 | Chemotherapy administration into peritoneal cavity requiring paracentesis |
315601005 | Ambulatory chemotherapy |
31652009 | Intracavitary chemotherapy for malignant neoplasm |
328331000119109 | Pancytopenia caused by non-steroidal anti-inflammatory agent |
363688001 | Administration of antineoplastic agent |
367336001 | Chemotherapy |
38216008 | Infusion chemotherapy for malignant neoplasm |
394894008 | Pre-operative chemotherapy |
394895009 | Postoperative chemotherapy |
394934009 | Combined preoperative chemotherapy and radiotherapy |
394935005 | Combined postoperative chemotherapy and radiotherapy |
399042005 | Chemotherapy cycle |
405165221000119107 | Long-term current use of belantamab mafodotin |
4114003 | Parenteral chemotherapy for malignant neoplasm |
428501000000108 | [V]Chemotherapy session for neoplasm |
450827009 | Induction chemotherapy |
483574341000119108 | Long-term current use of upadacitinib |
50050141000188100 | Anthracycline therapy |
51534007 | Oral chemotherapy for malignant neoplasm |
584833311000119102 | Long-term current use of guselkumab |
68619000 | Chemotherapy for non-neoplastic disease |
6872008 | Perfusion chemotherapy for malignant neoplasm |
700496000 | Postoperative administration of antineoplastic agent into peritoneal cavity |
703423002 | Combined chemotherapy and radiation therapy |
70446004 | Chemotherapy administration into pleural cavity requiring thoracentesis |
707311008 | Immunosuppressant drug therapy |
713517003 | Infliximab therapy |
713518008 | Mycophenolate therapy |
713551004 | Azathioprine therapy |
716872004 | Antineoplastic chemotherapy regimen |
720379009 | Hepatic arterial infusion chemotherapy |
721912451000119106 | Long-term current use of risankizumab |
722189006 | Abatacept therapy |
722472009 | Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
722482005 | Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
722491009 | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
723945004 | Cyclosporine therapy |
724159000 | Rituximab therapy |
724160005 | Tacrolimus therapy |
724165000 | Tofacitinib therapy |
726599006 | Sirolimus therapy |
726603006 | Apremilast therapy |
7447008 | Immunosuppressive therapy for transplant |
762315004 | Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent |
782708002 | Everolimus therapy |
782710000 | Natalizumab therapy |
782711001 | Secukinumab therapy |
782712008 | Vedolizumab therapy |
816151001 | Administration of consolidation antineoplastic agent |
824522871000119100 | History of chimeric antigen receptor T-cell immunotherapy |
829591000000101 | Neoadjuvant chemotherapy |
830155008 | Administration of hyperthermic antineoplastic agent into peritoneal cavity |
830156009 | Administration of hyperthermic antineoplastic agent into thoracic cavity |
836671891000119108 | Long-term current use of belatacept |
843671000000104 | Electrochemotherapy |
860788002 | Ocrelizumab therapy |
862921000000106 | Intravesical electrochemotherapy |
86553008 | Immunosuppressive therapy |
870249004 | Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen |
870250004 | Fluorouracil, leucovorin, irinotecan and oxaliplatin antineoplastic chemotherapy regimen |
870253002 | Myeloablative conditioning regimen |
87776000 | Intra-arterial infusion of antineoplastic agent |
890093004 | Administration of multiple antineoplastic agents |
897713009 | Antineoplastic chemoimmunotherapy |
950410381000119107 | Immunodeficiency caused by long term therapeutic use of immunosuppressant |
968171000000104 | Provision of high dose inhaled corticosteroid safety card |